miR-145, along with miR-130a, functions as a key regulator of myeloid cell reprogramming by targeting transforming growth factor-β receptor II (TβRII) and insulin-like growth factor 1 receptor (IGF1R), both of which are critical mediators of immunosuppressive signaling within the tumor microenvironment [109,110]. The gene discussed is IGF1R; the disease is neoplasm.